Noravax

Noravax, Inc. (NASDAQ: NVAX) announced positive results from pre-clinical safety studies of its virus-like particle (VLP) vaccine for respiratory syncytial virus (RSV). In the animal model, the vaccine was effective and well-tolerated, according to McNicoll, Lewis & Vlak. Three intramuscular...